Sex hormone associations with breast cancer risk and the mediation of randomized trial postmenopausal hormone therapy effects

Breast Cancer Research

Volumn 16, Issue 2, 2014, Pages

  Zhao, Shanshan ^a   Chlebowski, Rowan T ^b   Anderson, Garnet L ^a   Kuller, Lewis H ^c   Manson, JoAnn E ^d   Gass, Margery ^e   Patterson, Ruth ^f   Rohan, Thomas E ^g   Lane, Dorothy S ^h   Beresford, Shirley A A ⁱ   Lavasani, Sayeh ^j   Rossouw, Jacques E ^k   Prentice, Ross L ^a  

^a USA   (United States)

^b LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^h STONY BROOK UNIVERSITY   (United States)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

^j KARMANOS CANCER INSTITUTE   (United States)

^k NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL; ESTRONE; ESTRONE SULFATE; PLACEBO; SEX HORMONE; SEX HORMONE BINDING GLOBULIN; ESTROGEN; MEDROXYPROGESTERONE ACETATE;

ADULT; ARTICLE; ASSOCIATION; BREAST CANCER; CANCER PREVENTION; CANCER RISK; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; ESTRADIOL BLOOD LEVEL; ESTROGEN BLOOD LEVEL; ESTROGEN THERAPY; ESTRONE BLOOD LEVEL; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; LOGISTIC REGRESSION ANALYSIS; OUTCOME ASSESSMENT; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK REDUCTION; SINGLE BLIND PROCEDURE; THERAPY EFFECT; AGED; BLOOD; BREAST NEOPLASMS; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG COMBINATION; MIDDLE AGED; MULTICENTER STUDY; RISK FACTOR; STATISTICAL MODEL; TREATMENT OUTCOME;

AGED; BREAST NEOPLASMS; DRUG THERAPY, COMBINATION; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; ESTROGENS, CONJUGATED (USP); FEMALE; FOLLOW-UP STUDIES; GONADAL STEROID HORMONES; HUMANS; LOGISTIC MODELS; MEDROXYPROGESTERONE ACETATE; MIDDLE AGED; POSTMENOPAUSE; RISK FACTORS; TREATMENT OUTCOME;

EID: 84899058164     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3632     Document Type: Article

References (22)

1. Writing Group for the Women's Health Initiative Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002, 288:321-333. 10.1001/jama.288.3.321, 12117397, Writing Group for the Women's Health Initiative.
2. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, Khandekar J, Petrovitch H, McTiernan A, Women's Health Initiative Investigators Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA 2003, 289:3243-3253. 10.1001/jama.289.24.3243, 12824205, Women's Health Initiative Investigators.
3. Chlebowski RT, Kuller LH, Prentice RL, Stefanick ML, Manson JE, Gass M, Aragaki AK, Ockene JK, Lane DS, Sarto GE, Rajkovic A, Schenken R, Hendrix SL, Ravdin PM, Rohan TE, Yasmeen S, Anderson G, Women's Health Initiative Investigators Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 2009, 360:573-587. 10.1056/NEJMoa0807684, 3963492, 19196674, Women's Health Initiative Investigators.
4. Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, Manson JE, Stefanick ML, Ockene J, Sarto GE, Johnson KC, Wactawski-Wende J, Ravdin PM, Schenken R, Hendrix SL, Rajkovic A, Rohan TE, Yasmeen S, Prentice RL, Women's Health Initiative Investigators Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 2010, 304:1684-1692. 10.1001/jama.2010.1500, 20959578, Women's Health Initiative Investigators.
5. Women's Health Initiative Steering Committee Effects of conjugated equine estrogens in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004, 291:1701-1712. Women's Health Initiative Steering Committee.
6. Stefanick ML, Anderson GL, Margolis KL, Hendrix SL, Rodabough RJ, Paskett ED, Lane DS, Hubbell FA, Assaf AR, Sarto GE, Schenken RS, Yasmeen S, Lessin L, Chlebowski RT, Women's Health Initiative Investigators Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006, 295:1647-1657. 10.1001/jama.295.14.1647, 16609086, Women's Health Initiative Investigators.
7. Anderson GL, Chlebowski RT, Aragaki AK, Kuller LH, Manson JE, Gass M, Bluhm E, Connelly S, Hubbell FA, Lane D, Martin L, Ockene J, Rohan T, Schenken R, Wactawski-Wende J. Conjugated equine oestrogens and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomized placebo-controlled trial. Lancet Oncol 2012, 13:475-486.
8. Prentice RL, Chlebowski RT, Stefanick ML, Manson JE, Pettinger M, Hendrix SL, Hubbell FA, Kooperberg C, Kuller LH, Lane DS, McTiernan A, O'Sullivan MJ, Rossouw JE, Anderson GL. Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am J Epidemiol 2008, 167:1207-1216. 10.1093/aje/kwn044, 2670848, 18372396.
9. Prentice RL, Chlebowski RT, Stefanick ML, Manson JE, Langer RD, Pettinger M, Hendrix SL, Hubbell FA, Kooperberg C, Kuller LH, Lane DS, McTiernan A, O'Sullivan MJ, Rossouw JE, Anderson GL. Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. Am J Epidemiol 2008, 167:1407-1415. 10.1093/aje/kwn090, 2703736, 18448442.
10. Beral V, Reeves G, Bull D, Green J, the Million Women Study Collaborators Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst 2011, 103:296-305. 10.1093/jnci/djq527, 3039726, 21278356, the Million Women Study Collaborators.
11. Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, Anderson G, Howard BV, Thomson CA, LaCroix AZ, Wactawski-Wende J, Jackson RD, Limacher M, Margolis KL, Wassertheil-Smoller S, Beresford SA, Cauley JA, Eaton CB, Gass M, Hsia J, Johnson KC, Kooperberg C, Kuller LH, Lewis CE, Liu S, Martin LW, Ockene JK, O'Sullivan MJ, Powell L, Simon MS, et al. The Women's Health Initiative hormone therapy trials: overview of health outcomes during the intervention and post-stopping phases. JAMA 2013, 310:1353-1368. 10.1001/jama.2013.278040, 24084921.
12. Edlefsen KL, Jackson RD, Prentice RL, Janssen I, Rajkovic A, O'Sullivan MJ, Anderson G. The effects of postmenopausal hormone therapy on serum estrogen, progesterone and sex-hormone binding globulin levels in healthy postmenopausal women. Menopause 2010, 17:622-629. 2866828, 20215977.
13. Farhat GN, Parimi N, Chlebowski RT, Manson JE, Anderson G, Huang AJ, Vittinghoff E, Lee JS, Lacroix AZ, Cauley JA, Jackson R, Grady D, Lane DS, Phillips L, Simon MS, Cummings SR. Sex hormone levels and risk of breast cancer with estrogen plus progestin. J Natl Cancer Inst 2013, 105:1496-1503. 10.1093/jnci/djt243, 24041978.
14. Women's Health Initiative Study Group Design of the Women's Health Initiative Clinical Trial and Observational Study. Control Clin Trials 1998, 19:61-109. Women's Health Initiative Study Group.
15. Hays J, Hunt JR, Hubbell FA, Anderson GL, Limacher M, Allen C, Rossouw JE. The Women's Health Initiative recruitment methods and results. Ann Epidemiol 2003, 13:18-77.
16. Curb JD, McTiernan A, Heckbert SR, Kooperberg C, Stanford J, Nevitt M, Johnson KC, Proulx-Burns L, Pastore L, Criqui M, Daugherty S, Women's Health Initiative Morbidity and Mortality Committee Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol 2003, 13:122-128. Women's Health Initiative Morbidity and Mortality Committee.
17. Anderson GL, Manson J, Wallace R, Lund B, Hall D, Davis S, Shumaker S, Wang CY, Stein E, Prentice RL. Implementation of the Women's Health Initiative study design. Ann Epidemiol 2003, 13:5-17.
18. Prentice RL, Pyke R. Logistic disease incidence models and case-control studies. Biometrika 1979, 66:403-412.
19. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, Mulvihill JJ. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989, 81:1879-1886. 10.1093/jnci/81.24.1879, 2593165.
20. Rosner B. Percentage points for a generalized ESD many-outlier procedure. Technometrics 1983, 25:165-172.
21. Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, Thijssen JH. Classification and pharmacology of progestins. Maturitas 2008, 61:171-180. 10.1016/j.maturitas.2008.11.013, 19434889.
22. Obiorah I, Jordan C. Scientific rationale for postmenopausal delay in the use of conjugated equine estrogens among postmenopausal women that causes reduction in breast cancer incidence and mortality. Menopause 2013, 20:372-382. 3740456, 23921472.